drugset / Trial / NCT07146191
RE104 Radiolabeled Mass Balance (hAME) Study
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to characterize the absorption, metabolism and routes of excretion of RE104 and its metabolites in healthy volunteers. This study will quantify drug and metabolites in blood, urine, and feces samples collected before study drug administration and through at least 168 hours after SC dosing of \[14C\]-RE104.
Timeline
- Start
- 2025-08-19
- Primary completion
- 2025-10-02
- Completion
- 2025-10-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RE104 | Unknown | 30 mg | Subcutaneous |
Indications
No indication recorded.